“Sweet-P”: Molecule for Targeting Human Glucocorticoid Receptor Beta in Cancer

Description:

Project ID: D2016-49

IP Status: Provisional patent application # 62/306,209       

Invention Description and Novelty: GRβ has been shown to increase growth and migration of cancer cells. Newly designed molecule suppresses GRβ to inhibit expression and migration of the cancer. Sweet-P is the only compound that has been shown to regulate GRβ.

Applications: Treating GRβ-related diseases including bladder cancer, prostate cancer, lung cancer, leukemia, glioblastoma, liver cancer, breast cancer, lupus, and asthma, and methods for hindering migration of such cancers.

Value proposition:

•       Compositions and methods for treatment of GRβ-related diseases;

•       Reduced to Practice:

(1)       Sweet-P blocks GRβ expression in lung and prostate cancer cells, and

(2)       Sweet-P blocks GRβ expression and migration of bladder cancer cells;

•       Also included is a kit for preparing a pharmaceutical composition;

•       No special method needed--Sweet-P can be synthesized through any method suitable for PNA synthesis.

•       Ready for commercialization and will not require an expensive and lengthy product development period.

 

Patent Information:
Category(s):
Asthma
Cancer
Lupus
For Information, Contact:
Anne Izzi
Licensing Associate
The University of Toledo
419 530 6226
anne.izzi@utoledo.edu
Inventors:
Terry Hinds
Lucien McBeth
Keywords:
Bladder
Cancer
Glucocorticoid Receptor Beta
Lung
Lupus
Prostate